Objective: Body composition impacts physical function and mortality. We compared long-term body composition changes after antiretroviral therapy (ART) initiation in HIVinfected individuals to that in HIV-uninfected controls.
Introduction
With continued improvements in survival, managing chronic conditions and optimizing overall health is becoming a primary concern in the care of HIV-infected individuals. Changes in body composition such as central fat accumulation and loss of muscle mass may impact physical function and mortality [1, 2] . Frailty has been reported to be approximately four-fold more common in HIV-infected individuals than in HIV-uninfected controls [3, 4] , with associations seen between frailty and both sarcopenia and central obesity [5, 6] .
Several studies have evaluated changes in body composition during the first 2 years after antiretroviral therapy (ART) initiation [7] [8] [9] [10] [11] . However, there is a paucity of studies reporting longer term body composition changes in ART-treated individuals, and no study to our knowledge has compared longer term body composition changes in HIV-infected individuals initiating ART with changes in HIV-uninfected controls. The aim of this study is to use a well characterized study population to evaluate longer term ($7.5 years) body composition change after ART initiation as part of a randomized trial and to compare this rate of change with that observed in HIV-uninfected individuals.
Methods
Participants and study procedures ART-naïve, HIV-1-infected individuals enrolled in AIDS Clinical Trials Group (ACTG) A5202 were randomized to atazanavir/ritonavir (ATV/r) or efavirenz (EFV) combined with either tenofovir disoproxil fumarate/ emtricitabine (TDF/FTC) or abacavir/lamivudine during the years 2005-2007 [12] . Those who agreed to participate in the metabolic substudy, ACTG A5224s, had baseline and follow-up whole body dual-energy xray absorptiometry (DXA) performed, with the A5224s primary body composition endpoints reported at 96 weeks after ART initiation [9] .
For the current study, in 2013-2014, we attempted to contact all participants, regardless of current ART, who were previously enrolled in ACTG A5224s (n ¼ 269). Study participants had one follow-up whole body DXA performed. All DXAs were standardized at the participating sites, then read and compared with prior scans centrally (Tufts University, Boston, Massachusetts, USA).
Changes in bone mineral density from this study have been reported elsewhere [13] .
We obtained a medical and medication history and administered to participants questionnaires capturing substance use and physical activity [14] . Participants underwent a physical examination, including measurement of height and weight. Each participant provided written informed consent prior to study enrollment. The study was approved by the institutional review board at each site.
HIV-uninfected controls
For comparison with HIV-uninfected individuals, we utilized participant-level data from two multiethnic longitudinal studies that performed serial whole body DXA in young men and women. The Boston Area Community Health/Bone Survey performed DXA at baseline and 7-year follow-up in 692 HIV-uninfected men [15] . From the metabolic substudy of the Women's Interagency HIV Study, we utilized whole body DXA results at baseline and 5-year follow-up in 122 HIVuninfected women [16] . We excluded data from HIVuninfected participants in these studies outside the sexspecific age window of the HIV-infected study participants (age range of HIV-infected men and women at initial DXA was 20-64 and 23-55 years, respectively) and assumed a linear rate of body composition change among HIV-uninfected individuals.
Statistical analyses
We used repeated measures analyses using piecewise slopes to compare the rate of body composition change (i.e., lean mass and total, trunk, and limb fat changes) between HIV-infected and HIV-uninfected individuals during the first 96 weeks of study (the 'early' period) and from 96 weeks to the end of study follow-up (the 'late' period), adjusting for age, sex, race, self-reported physical activity level, and cigarette and alcohol use.
In HIV-infected individuals, we compared the rate of body composition change during the early vs. late period. We performed univariate and multivariable analyses to examine associations during the early and late periods between body composition change and age, sex, race/ ethnicity, randomized ART regimen, and baseline and time-updated CD4 þ T-cell count and HIV-1 RNA level. Factors with a univariate P value of less than 0.20 were included into multivariable models, which used backward selection and retained factors with a P value of less than 0.05.
All analysis testing was two-sided with a type I error of 5%; thus, P values less than 0.05 were considered statistically significant with no adjustment for multiple comparisons.
Results

Participant characteristics
Ninety-seven of the original 269 participants from ACTG A5224s were available for repeat DXA and enrolled in the current study. The baseline characteristics between those ACTG A5224s participants who did and did not enroll in the current study did not differ significantly (data not shown). Table 1 displays the characteristics of the 97 HIV-infected individuals and 614 HIV-uninfected controls. Compared with HIV-uninfected controls, HIV-infected individuals were younger, were more likely to be white nonHispanic, had a lower median BMI at both initial and final DXA, and had a higher rate of individuals who never smoked and reported low-to-moderate alcohol consumption. The median time interval between the initial and final DXA in HIV-infected participants and controls was 7.6 and 6.9 years, respectively.
Among HIV-infected participants, the median age at initial DXA was 40 years. Eighty-six percent of participants were male. The median CD4 þ T-cell count at initial and final DXA was 247 and 598 cells/ml, respectively. The median HIV-1 RNA level at initial DXA was 4.6 log 10 copies/ml, and 86% of participants had an HIV RNA level less than 200 copies/ml at the final DXA. The median exposure to a protease inhibitor during study follow-up was 3.7 years. Forty-five percent of HIV-infected participants were on a ritonavir-boosted protease inhibitor at final DXA.
Body composition changes in HIV-infected vs. controls during the early period Figure 1a displays the unadjusted change in total lean mass in HIV-infected vs. HIV-uninfected individuals. During the first 96 weeks of study follow-up (i.e. 'the early period') after adjustment for age, sex, race, self-reported physical activity level, and cigarette and alcohol use, HIVinfected individuals gained significantly more lean mass Body composition after antiretroviral therapy initiation Grant et al. 2807 Factors associated with body composition change in HIV-infected individuals during the early period Table 2 displays the univariate and multivariable analyses of factors associated with change in lean mass. In univariate analyses, both baseline lower CD4 þ T-cell count and higher HIV-1 RNA level were associated with a greater increase in lean mass during the first 96 weeks after ART initiation (P < 0.001 for both). In multivariable analysis, lower baseline CD4 þ T-cell count remained significantly associated with a greater gain in lean body mass (P < 0.001). Table 3 displays the univariate and multivariable analyses of factors associated with change in total body fat in the early period. In univariate analyses, lower baseline CD4 þ T-cell count and higher baseline HIV-1 RNA level were associated with greater gains in total body fat (P < 0.001 and P ¼ 0.002, respectively). As was seen for lean mass, in multivariable analysis, lower baseline CD4 þ T-cell count was associated with a greater increase in total body fat (P ¼ 0.001).
Covariates associated with changes in trunk and limb fat were identical to the associations with total body fat. In univariate analyses, lower baseline CD4 þ T-cell count and higher baseline HIV-1 RNA level were significantly associated with greater increases in trunk fat (P ¼ 0.001 and 0.002, respectively) and limb fat (P ¼ 0.001 and 0.003, respectively). In multivariable analyses, lower baseline CD4 þ T-cell count remained associated with greater gains in trunk fat (P ¼ 0.001) and limb fat (P ¼ 0.002).
Factors associated with body composition change in HIV-infected individuals during the late period As shown in Table 2 , during the late period in univariate analyses, older age and black, non-Hispanic race were associated with loss of lean mass (P ¼ 0.007 and 0.017, respectively). Both these factors remained significantly associated with loss of lean mass in multivariable analysis (P ¼ 0.002 and 0.003, respectively).
As shown in Table 3 , older age was associated with a smaller increase in total fat in univariate analyses (P ¼ 0.010) and both older age and female sex were associated with a smaller increase in total fat in multivariable analysis (P ¼ 0.008 and 0.023, respectively). during the late period were similar to those associated with changes in total fat (data not shown). In the late period, there was no relationship between any HIVrelated factor and change in any component of body composition.
Factors associated with changes in trunk and limb fat
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Discussion
We compared changes in body composition over a median of approximately 7.5 years after ART initiation in 97 HIV-infected individuals to changes in HIV-uninfected controls. After adjustment for potential confounders, we found that during the first 96 weeks after ART initiation HIV-infected individuals had significantly greater increases in lean mass and total fat than HIVuninfected individuals. Consistent with a 'return to health effect', those HIV-infected individuals with a lower baseline CD4 þ T-cell count and a higher HIV-1 viral load had greater increases in lean mass and total, trunk, and limb fat.
In a novel finding, we found that there was a significant trajectory change in body composition in HIV-infected individuals after 96 weeks of ART. Compared with HIVuninfected, we found that HIV-infected individuals lost lean body mass and gained fat during the late period, after controlling for potential confounders including differences in self-reported physical activity. The loss of lean mass occurred despite virologic suppression in a substantial majority of our participants. During the late period, there were no significant relationships between HIV-disease-related measures such as CD4 þ T-cell count and HIV-1 viral load and change in body composition. In addition, we found no relationship between randomization to a protease inhibitor in the parent study (ATV/r in A5202) and changes in body composition, in line with a recent report of similar changes in body composition between those randomized to raltegravir vs. darunavir/ ritonavir or ATV/r [7] . Finally, consistent with what has been reported in the general population and in other studies of HIV-infected individuals [17, 18] , older age was associated with loss of lean mass during the late period.
We are not aware of any studies that have evaluated longer term changes in body composition in HIV-infected individuals after ART initiation. The majority of analyses have been limited to 48-96 weeks [7] [8] [9] [10] [11] . In addition, many studies report body composition changes with older antiretroviral agents that have more metabolic side effects and mitochondrial toxicity than the agents used in our study [8, 10, 11] . The finding that HIV-infected persons gain more fat but lose lean mass after the first 96 weeks of ART compared with HIV-uninfected controls has not been reported by others. These changes might be missed in clinical care if only BMI but not body composition is measured. The Fat Redistribution and Metabolic Change in HIV infection (FRAM) Study found that HIV-infected individuals followed for 5 years had similar changes in muscle mass and total fat as HIV-uninfected controls [18, 19] . There are several differences between the FRAM Study and the current study that may account for the differences in results. The FRAM Study captured individuals at various stages of ART use (i.e. some individuals initiated ART during study follow-up), so some of the gain of lean mass associated with ART initiation may have been counterbalanced by the loss of lean mass that could have occurred later after ART initiation. In addition, the FRAM Study had a larger percentage of HIV-infected women (33%) than our study (14%). In the FRAM Study, HIV-infected women appeared to have more favorable changes in muscle mass compared with men [18] . Also, 44% of FRAM participants were viremic and, for a substantial portion of study follow-up, some participants were on stavudine, an older antiretroviral drug with well described negative effects on peripheral fat [20] . Both these factors could have affected fat accumulation [21] .
It is unclear mechanistically why individuals in our study would continue to gain fat but lose lean mass after the first 96 weeks of ART compared with HIV-uninfected individuals. Several studies in HIV-infected individuals have shown a relationship between elevated proinflammatory cytokines such as IL-6 and high-sensitivity Creactive protein and fat gain and loss of lean mass [7, 22, 23] . It is possible that the chronic proinflammatory state that persists in treated HIV infection could account for the adverse changes in body composition seen during extended follow-up in our study.
There are several limitations of our study that deserve mentioning. Few women were enrolled in our study. The control populations were not specifically recruited for this study, and there could be unmeasured factors that could account for the difference in body composition changes seen between the HIV-infected and the control groups. We did not have data on testosterone levels, and different rates of hypogonadism could account for differences in body composition change between HIV-infected and controls. We analyzed randomization to ATV/r and to TDF/FTC as covariates in our multivariable analyses but many individuals did not remain on their originally randomly assigned study medication throughout study follow-up. The control population had a slight increase in lean mass and total fat during study follow-up. Given the relative young age of the HIV-uninfected population, these changes are similar to what have been reported elsewhere [24] . The differences in body composition change between the HIV-infected and HIV-uninfected populations were relatively modest; however, the adverse trajectory in lean mass and total fat could be compounded in persons with preexisting wasting or if the loss continues beyond the time period we evaluated. In addition, this was an HIV-infected study population with relatively high-reported levels of physical activity; the changes in body composition may be even less favorable in more sedentary individuals.
In addition, integrase inhibitors are now commonly used in industrialized countries as the anchor agent, and EFV and protease inhibitors are being less frequently used. It is unclear whether our results would extend to individuals on integrase inhibitor-containing antiretroviral regimens, although recent data suggest similar changes in body composition changes in participants on integrase inhibitors vs. newer protease inhibitors, at least over the first 96 weeks of ART [7] . We did not have data on visceral adiposity. However, studies in which individuals are treated with newer antiretroviral therapies suggest that changes in visceral fat are proportional to those seen in the total and trunk fat [7] . In addition, as we performed multiple comparisons, marginally significant associations should be interpreted cautiously.
In conclusion, we found that compared with HIVuninfected controls, HIV-infected individuals gained more fat but lost lean mass after the first 2 years of ART. Several studies suggest that HIV-infected individuals have higher rates of frailty when compared with HIVuninfected individuals [3, 4] , and our findings could provide an explanation for these observations if the adverse body composition changes found during the late period continue beyond the time period we evaluated. Furthermore, our data suggest the need for interventions to maintain or increase lean mass and reduce fat accumulation to preserve physical functioning in longterm-treated HIV-infected individuals.
